Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.

DLBCL PET/CT lymphoma mutational profile prognostic index

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Feb 2022
Historique:
received: 13 12 2021
revised: 10 02 2022
accepted: 14 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Accurate estimation of the progression risk after first-line therapy represents an unmet clinical need in diffuse large B-cell lymphoma (DLBCL). Baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters, together with genetic analysis of lymphoma cells, could refine the prediction of treatment failure. We evaluated the combined impact of mutation profiling and baseline PET/CT functional parameters on the outcome of DLBCL patients treated with the R-CHOP14 regimen in the SAKK38/07 clinical trial (NCT00544219). The concomitant presence of mutated

Identifiants

pubmed: 35205765
pii: cancers14041018
doi: 10.3390/cancers14041018
pmc: PMC8870624
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Leukemia. 2016 Dec;30(12):2385-2395
pubmed: 27198204
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1142-1154
pubmed: 29460024
Oncotarget. 2017 Aug 24;8(59):99587-99600
pubmed: 29245926
J Hematol Oncol. 2017 Mar 17;10(1):70
pubmed: 28302137
Am J Hematol. 2015 Sep;90(9):790-5
pubmed: 26096944
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19
pubmed: 26902371
Blood Adv. 2020 Mar 24;4(6):1082-1092
pubmed: 32196557
Blood. 2020 Apr 16;135(16):1396-1405
pubmed: 31978225
Am J Hematol. 2019 May;94(5):604-616
pubmed: 30859597
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Syst Biol. 2004 Oct;53(5):793-808
pubmed: 15545256
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Blood. 2018 Jul 12;132(2):179-186
pubmed: 29720487
J Nucl Med. 2020 Jan;61(1):40-45
pubmed: 31201248
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Blood. 2014 Feb 6;123(6):837-42
pubmed: 24264230
J Clin Oncol. 2015 Aug 10;33(23):2523-9
pubmed: 26150440
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1417-1427
pubmed: 30941463
Metabolites. 2021 Jan 26;11(2):
pubmed: 33530590
Clin Cancer Res. 2016 Aug 1;22(15):3801-9
pubmed: 26936916
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1463-1464
pubmed: 29651546
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Blood. 2020 May 14;135(20):1759-1771
pubmed: 32187361
Oncotarget. 2016 Dec 13;7(50):83544-83553
pubmed: 27835875
J Nucl Med. 2019 Aug;60(8):1096-1102
pubmed: 30954945
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Ann Nucl Med. 2021 Jan;35(1):24-30
pubmed: 33001389
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Br J Haematol. 2022 Feb;196(4):814-829
pubmed: 34467527
Hematol Oncol. 2020 Dec;38(5):715-725
pubmed: 32947651
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
J Hematol Oncol. 2015 Jun 14;8:70
pubmed: 26071053
Nature. 2011 Mar 10;471(7337):189-95
pubmed: 21390126
Br J Haematol. 2017 Oct;179(1):50-60
pubmed: 28653407
J Cancer. 2019 Jan 1;10(2):323-331
pubmed: 30719126
Clin Cancer Res. 2016 Jul 1;22(13):3414-5
pubmed: 27371634
Science. 2008 Mar 21;319(5870):1676-9
pubmed: 18323416
Front Oncol. 2021 Mar 11;11:628807
pubmed: 33777778
Mod Pathol. 2020 Dec;33(12):2422-2436
pubmed: 32620919
Cancer Med. 2018 Jan;7(1):114-122
pubmed: 29239133
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):623-33
pubmed: 25573631
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Eur J Nucl Med Mol Imaging. 2018 May;45(5):680-688
pubmed: 29344718

Auteurs

Sofia Genta (S)

Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Guido Ghilardi (G)

Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Luciano Cascione (L)

Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland.

Darius Juskevicius (D)

Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Alexandar Tzankov (A)

Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Sämi Schär (S)

Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, 3008 Bern, Switzerland.

Lisa Milan (L)

Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Maria Cristina Pirosa (MC)

Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Fabiana Esposito (F)

Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Teresa Ruberto (T)

Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Luca Giovanella (L)

Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland.

Stefanie Hayoz (S)

Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, 3008 Bern, Switzerland.

Christoph Mamot (C)

Division of Oncology, Cantonal Hospital Aarau, 5001 Aarau, Switzerland.

Stefan Dirnhofer (S)

Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Emanuele Zucca (E)

Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Department of Medical Oncology, Bern University Hospital, University of Bern, 3008 Bern, Switzerland.

Luca Ceriani (L)

Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Clinic of Nuclear Medicine and PET/CT Center, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.

Classifications MeSH